Alebund Pharmaceuticals
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1206 Hong Kong Plaza South Tower 283 Cen...Phone Number
+86 2160836212Website
www.alebund.comRevenue
$15.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Alebund Pharmaceuticals
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.Explore more
Popular SearchesAlebund PharmaceuticalsAlebund Pharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Show moreAlebund Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alebund Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alebund Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Check if Alebund Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Alebund Pharmaceuticals is spiking on competitors!
Alebund Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alebund Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alebund Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Alebund Pharmaceuticals
Earning: See what the market has to say on Alebund Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Alebund Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Alebund Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alebund Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alebund Pharmaceuticals.
Alebund Pharmaceuticals financials insights
Gather financial insights about Alebund Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$60M
Other Financing Round
$54.5M
2025
Series C
$70.1M
Alebund Pharmaceuticals Tech Stack
A closer look at the technologies used by Alebund Pharmaceuticals
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Alebund Pharmaceuticals News & Media
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1...R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority of AP301 to sevelamer carbonate in...Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority of AP301 to sevelamer carbonate in reducing serum phosphate levels was demonstrated. Overall, AP301 was safe and well-tolerated. The most common AEs were discolored feces and diarrhea. Diarrhea generally occurred early and resolved without treatment
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Alebund Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.... Read More
